Literature DB >> 7811050

Penetration of cefprozil into middle ear fluid of patients with otitis media.

W C Shyu1, J Haddad, J Reilly, W N Khan, D A Campbell, Y Tsai, R H Barbhaiya.   

Abstract

Penetration of cefprozil into the middle ear fluid was investigated in patients with chronic otitis media. A total of 89 patients ranging from 7 months to 11 years old participated in the study. The middle ear fluid was removed by ventilation tubes inserted through the tympanic membrane at times ranging from 0.38 to 5.97 h after oral administration of a single dose of 15 or 20 mg/kg of body weight. A blood sample was also collected as soon as the middle ear fluid was removed. Plasma samples were analyzed for the concentration of cefprozil by a high-performance liquid chromatographic assay. Middle ear fluid samples were analyzed for the concentration of cefprozil by a microbiological assay. The concentrations of cefprozil in plasma ranged from 0.38 to 15.97 micrograms/ml at the 15-mg/kg dose level and from 1.28 to 21.47 micrograms/ml at the 20-mg/kg dose level. The corresponding middle ear fluid concentrations of cefprozil ranged from 0.06 to 4.44 micrograms/ml and from 0.17 to 8.67 micrograms/ml, respectively. Cefprozil penetrates well into middle ear fluid in patients with chronic otitis media.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7811050      PMCID: PMC284715          DOI: 10.1128/AAC.38.9.2210

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  In vitro activity of BMY-28100 against common isolates from pediatric infections.

Authors:  R K Scribner; M I Marks; B D Finkhouse
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

2.  Comparative antibacterial activity of a new oral cephalosporin, BMY-28100.

Authors:  N X Chin; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

3.  Concentrations of antimicrobial agents in middle ear fluid, saliva and tears.

Authors:  J D Nelson; C M Ginsburg; O Mcleland; J Clahsen; M C Culbertson; H Carder
Journal:  Int J Pediatr Otorhinolaryngol       Date:  1981-12       Impact factor: 1.675

4.  Study of diffusion of cefuroxime into middle ear effusions of patients with chronic purulent otitis media.

Authors:  A Martini; L Xerri
Journal:  J Antimicrob Chemother       Date:  1982-09       Impact factor: 5.790

Review 5.  Comparison of cefprozil with other antibiotic regimens in the treatment of children with acute otitis media.

Authors:  H R Stutman; A G Arguedas
Journal:  Clin Infect Dis       Date:  1992-06       Impact factor: 9.079

6.  BMY 28100, a new oral cephalosporin.

Authors:  F Leitner; T A Pursiano; R E Buck; Y H Tsai; D R Chisholm; M Misiek; J V Desiderio; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1987-02       Impact factor: 5.191

7.  Comparison of rosaramicin and erythromycin stearate for treatment of cervical infection with Chlamydia trachomatis.

Authors:  H G Robson; P P Shah; R G Lalonde; L Hayes; V M Senikas
Journal:  Sex Transm Dis       Date:  1983 Jul-Sep       Impact factor: 2.830

8.  Chlamydia trachomatis infections in the United States. What are they costing us?

Authors:  A E Washington; R E Johnson; L L Sanders
Journal:  JAMA       Date:  1987-04-17       Impact factor: 56.272

9.  In vitro activity of A-56268 (TE-031) and four other antimicrobial agents against Chlamydia trachomatis.

Authors:  J Segreti; H A Kessler; K S Kapell; G M Trenholme
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

10.  In vitro activity of Ro 15-8074, Ro 19-5247, A-56268, and roxithromycin (RU 28965) against Neisseria gonorrhoeae and Chlamydia trachomatis.

Authors:  W R Bowie; C E Shaw; D G Chan; W A Black
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  4 in total

1.  Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model.

Authors:  D M Cappelletty; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

2.  Pharmacokinetics of cefprozil in plasma and middle ear fluid: in children undergoing treatment for acute otitis media.

Authors:  David P Nicolau; Christina A Sutherland; Adriano Arguedas; Ron Dagan; Micheal E Pichichero
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 3.  Cefprozil: a review.

Authors:  Sumit Bhargava; Rakesh Lodha; S K Kabra
Journal:  Indian J Pediatr       Date:  2003-05       Impact factor: 1.967

4.  Efficacy and tolerability assessment of cefprozil in children with acute otitis media.

Authors:  Nomeeta Gupta; Vivek Bagga; Bharat J Parmar; Kishaloy Kar; Abhijit Mukherjee; Sandip Mehta; Ashok K Moharana
Journal:  Indian J Pediatr       Date:  2004-04       Impact factor: 1.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.